Document Classification

Section Type: RESULTS

Text: Based on the placebo-controlled trials, iloperidone improvements from baseline (least squared mean change standard error) were as follows : excitement/hostility, 0. 4 0. 21 for 10-16 mg, 0. 6 0. 43 for 20-24 mg vs. -1. 0 0. 23 for placebo ; P < 0. 001 for both iloperidone doses vs. placebo ; depression/anxiety, 1. 9 0. 21 for 10-16 mg, 1. 9 0. 41 for 20-24 mg vs. 1. 1 0. 22 for placebo ; P < 0. 05 for 10-16 mg dose vs. placebo ; cognition, 2. 8 0. 35 for 10-16 mg, 3. 9 0. 69 for 20-24 mg vs. 1. 6 0. 38 for placebo ; P < 0. 05 for both iloperidone doses vs. placebo ; positive, 3. 7 0. 26 for 10-16 mg, 4. 1 0. 53 for 20-24 mg vs. 2. 7 0. 29 for placebo ; P < 0. 05 for both iloperidone doses vs. placebo ; and negative, 2. 2 0. 29 for 10-16 mg, 2. 5 0. 58 for 20-24 mg vs. 1. 3 0. 32 for placebo ; P < 0. 05 for 10-16 mg vs. placebo.